1. Genmab holds a virtual R&D Update today, showcasing future innovations. 2. The event covers data review from the ASH meeting, highlighting cancer therapeutics. 3. Genmab's pipeline includes advanced bispecific T-cell engagers and antibody-drug conjugates. 4. Forward-looking statements emphasize potential risks in product development and growth. 5. By 2030, Genmab aims for groundbreaking advancements in antibody medicines.
FAQ
Why Bullish?
Genmab's meeting could signal positive advancements and investor interest, boosting confidence.
How important is it?
The R&D update is crucial for investors assessing Genmab's future prospects in cancer treatment.
Why Long Term?
The emphasis on future innovations points to sustained growth potential and biotechnology advancements.
Genmab to Host 2025 R&D Update and ASH Data Review Meeting
Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) is scheduled to conduct its 2025 Research and Development (R&D) Update and ASH Data Review Meeting today, December 11, 2025, at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will be held virtually and accessible via live webcast. Interested participants can register for the webinar here. An archived version of the webcast will also be available on Genmab’s official website.
Event Details and Accessibility
This online meeting is not part of the official ASH Annual Meeting agenda but serves to update stakeholders on Genmab's latest advancements. The webcast will provide critical insights into the company's ongoing projects and innovative solutions in the biotechnology sector.
About Genmab: Innovating for Patient Care
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab is recognized as a leading biotechnology company. With a fundamental goal of improving patient outcomes through innovative therapeutic solutions, Genmab has been at the forefront of developing differentiated antibody therapies for over 25 years. The company is dedicated to expanding its proprietary pipeline, which includes:
- Bispecific T-cell engagers
- Antibody-drug conjugates
- Next-generation immune checkpoint modulators
- Effector function-enhanced antibodies
Vision and Future Goals
By 2030, Genmab aims to dramatically enhance the lives of individuals suffering from cancer and other serious diseases through what it describes as “knock-your-socks-off” (KYSO) antibody medicines®. This ambitious vision aligns with the company's commitment to pioneering advancements in antibody technology and therapies, significantly influencing patient care.
Contact Information
For further inquiries, please reach out to:
- Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Phone: +1 609 524 0065
Email: mmp@genmab.com - Andrew Carlsen, Vice President, Head of Investor Relations
Phone: +45 3377 9558
Email: acn@genmab.com
Forward-Looking Statements
This release contains forward-looking statements that can be identified by terms such as “believe,” “expect,” “anticipate,” “intend,” and other similar expressions. Actual results may differ materially due to a variety of factors including clinical development risks, market acceptance, and technological advancements. For more information on potential risks, please refer to Genmab’s recent financial reports and the risk factors outlined in the most recent Annual Report on Form 20-F on file with the U.S. Securities and Exchange Commission (SEC) available at www.sec.gov.